SEC EDGARSEP 41 min read$ILMN

Meister Keith A. sold $57.2M of ILMN (indirect holdings)

Meister Keith A. sold 263,560 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $217.03 ($213.20–$221.55, $57.20M total) across 12 trades over 2026-09-02 to 2026-09-04.

Original reporting

SEC EDGAR · Meister Keith A.

Published Sep 4, 2026, 10:43 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 4, 2026, 10:47 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ILMN

Bearish

high confidence

Mentioned

$ILMN

Relevance

8/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ILMNBearishMed

Why it matters

The $57.2M sale is the first public disclosure of this insider activity, providing new data for traders.

Market read

First‑report insider sale of significant size; may influence short‑term price action and sentiment in the biotech sector.

What to watch

The sale was executed via multiple small trades and may reflect personal tax planning rather than company outlook.

Relevance 8/10Novelty 8/10Timing: post‑market filing on 2026‑09‑04

Background

SEC Form 4 filing discloses insider transactions; director sales are monitored for signals about company health.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ILMNBearishHigh confidence

Context

Director Meister Keith A. sold 263,560 shares worth $57.2M, reducing his stake to 770,350 shares.

Expected impact

Short-term price dip expected as market digests the $57M sale.

Evidence & confidence

The sale size is material for a mid‑cap biotech and is disclosed for the first time via a Form 4 filing.

Market effects

Sector

May raise concerns for other diagnostics and genomics firms as insider confidence is questioned.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact beyond Illumina shareholders.

Counterpoint

What could challenge this read

Insider sales can be routine liquidity events; the market may overreact to the headline.

Key entities

Company
Illumina, Inc.
US‑listed genomics and diagnostics firm (ticker ILMN).
Individual
Meister Keith A.
Director of Illumina who executed the share sale.

Read at source ← All news

OCT 26

$MRNAMed

Moderna’s Rally May Have Run Out of Steam. Here’s What to Watch Next

Moderna (MRNA) shares fell 20% after leaked trial data for its melanoma vaccine, despite analysts calling results 'strong.' The drop may signal the end of its 700% year-to-date rally. Merck (MRK), partnering on the vaccine, saw minimal impact. Analysts expect Merck to report strong earnings. BioNTech (BNTX) and Illumina (ILMN) are also mentioned.

aol.com3 min

OCT 13

$ILMNMed

Illumina Launches $1.0 Billion Unsecured Commercial Paper Program; Signs Dealer Agreements

Illumina established a $1.0 billion unsecured commercial paper program for general corporate purposes. The program allows short-term notes with maturities up to 397 days. A national bank will serve as the issuing and paying agent, with three dealers initially participating. No notes were outstanding as of the filing date.

tradingview.com1 min

OCT 5

$ILMNMed

Illumina (ILMN) Shares Skyrocket, What You Need To Know

Illumina (ILMN) shares rose 7.7% after analysts raised price targets, citing expected clinical sales growth and AI applications. The stock closed at $293.84, up 7.6%. Illumina's shares have seen significant volatility, with a 22.4% gain last year on strong earnings. The company has raised its full-year EPS guidance to $4.70. ILMN is up 119% YTD, reaching a 52-week high.

financialcontent.com2 min

SEP 24

$ILMNHighAI 8/10

Illumina Soars to New High After Index Win

Illumina (ILMN) shares hit a 52-week high after being added to the S&P 500 Equal Weighted Index. The company announced a $300M note offering, strong earnings, and raised full-year guidance. Analysts increased price targets, citing sustainable earnings and clinical sequencing demand. The stock's rise is driven by index inclusion, debt refinancing, and upgraded guidance, with future growth expected from its sequencer business model.

tipranks.com2 min

SEP 23

$GRALMed

This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

morningstar.com6 min

SEP 18